AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10215093 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasks varying difficulty of access to procedural memory
Number of subjects: 12
Study 9485967 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.0625% with fentanyl 2.5 micrograms.ml‐1 at a rate of 10‐12 ml.h‐1
Number of subjects: 2
Study 9485967 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.125% alone
Number of subjects: 2
Study 2166716 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble dietary fibre supplement (7 g/day for 2 weeks)
Number of subjects: 19
Study 2166716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 7106067 — intervention group
Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 11
Study 7106067 — intervention group
Group type: EXPERIMENTAL
Intervention: 233 μg/m3 sulfuric acid
Number of subjects: 11
Study 7106067 — intervention group
Group type: EXPERIMENTAL
Intervention: 418 μg/m3 sulfuric acid
Number of subjects: 11
Study 7106067 — intervention group
Group type: EXPERIMENTAL
Intervention: 939 μg/m3 sulfuric acid
Number of subjects: 11
Study 30632152 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic membrane (AM)
Number of subjects: 148
Study 30632152 — intervention group
Group type: COMPARATOR
Intervention: Temporalis fascia (control)
Number of subjects: 148
Study 28063158 — intervention group
Group type: EXPERIMENTAL
Intervention: Volitionally induced muscle cramps (VIMCs)
Number of subjects: 15
Study 26963842 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexpiprazole 3 mg/day
Number of subjects: 97
Study 26963842 — intervention group
Group type: COMPARATOR
Intervention: Aripiprazole 15 mg/day
Number of subjects: 97
Study 25206295 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic combination (Lactobacillus acidophilus ATCC 700396 and Bifidobacterium lactis ATCC SD5220)
Number of subjects: 0
Study 25206295 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic combination
Number of subjects: 0
Study 25206295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21999398 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation (3 grams/day, 90 days)
Number of subjects: 14
Study 21999398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 20397080 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% Cellulose Sulfate microbicide gel
Number of subjects: 0
Study 17917625 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of prednisolone for 6 weeks followed by topical application of 2% minoxidil for 14 weeks
Number of subjects: 0
Study 17917625 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of prednisolone and minoxidil
Number of subjects: 0
Study 16086923 — intervention group
Group type: EXPERIMENTAL
Intervention: TnT-positive group (TnT > or = 0.1 ng/mL)
Number of subjects: 113
Study 16086923 — intervention group
Group type: EXPERIMENTAL
Intervention: TnT-positive group (TnT > or = 0.03 ng/mL)
Number of subjects: 113
Study 16086923 — intervention group
Group type: EXPERIMENTAL
Intervention: TnT-positive group (TnT > or = 0.01 ng/mL)
Number of subjects: 113
Study 16086923 — intervention group
Group type: EXPERIMENTAL
Intervention: TnT-positive group
Number of subjects: 113
Study 12161826 — intervention group
Group type: EXPERIMENTAL
Intervention: Center-based exercise (endurance, strength, balance, flexibility) 3 times weekly for months 1 to 6, once weekly for months 7 to 12 with home exercise 2 sessions a week, and at home only for months 13 to 18
Number of subjects: 155
Study 12161826 — intervention group
Group type: EXPERIMENTAL
Intervention: Center-based exercise
Number of subjects: 155
Study 12161826 — intervention group
Group type: COMPARATOR
Intervention: Home endurance exercise (control)
Number of subjects: 155
Study 10444056 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% topical ciprofloxacin presoaked in disposable soft contact lenses for 10-12 hours, applied for 3 hours (Group A)
Number of subjects: 3
Study 10444056 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% topical ciprofloxacin presoaked in disposable soft contact lenses for 10-12 hours, applied for 5-6 hours (Group B)
Number of subjects: 3
Study 10444056 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% topical ciprofloxacin presoaked in disposable soft contact lenses for 10-12 hours, applied for 8-12 hours (Group C)
Number of subjects: 3
Study 7484829 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin treatment
Number of subjects: 6000
Study 2399774 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery and chemotherapy (combination of bleomycin, vincristine, mitomycin-C, and cisplatin; later carboplatin and bleomycin)
Number of subjects: 32
Study 2399774 — intervention group
Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 32
Study 2399774 — intervention group
Group type: COMPARATOR
Intervention: Surgery and postoperative radiotherapy
Number of subjects: 32
Study 7365120 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback training (contingent feedback)
Number of subjects: 50
Study 7365120 — intervention group
Group type: COMPARATOR
Intervention: Noncontingent biofeedback training
Number of subjects: 50
Study 7365120 — intervention group
Group type: COMPARATOR
Intervention: Analogous external placebo (brain wave stimulator)
Number of subjects: 50
Study 7365120 — intervention group
Group type: COMPARATOR
Intervention: Concentration exercise (internal attribution)
Number of subjects: 50
Study 7365120 — intervention group
Group type: COMPARATOR
Intervention: Combination of brain wave stimulator and concentration exercise
Number of subjects: 50
Study 7365120 — intervention group
Group type: COMPARATOR
Intervention: Unaided efforts
Number of subjects: 50
Study 30829698 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic distal gastrectomy (LDG)
Number of subjects: 1011
Study 30829698 — intervention group
Group type: COMPARATOR
Intervention: Open distal gastrectomy (ODG)
Number of subjects: 1011
Study 28843184 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI plus cetuximab
Number of subjects: 0
Study 28843184 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI plus bevacizumab
Number of subjects: 0
Study 25997818 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganetespib (150 mg/m² on days 1 and 15) in combination with Docetaxel (75 mg/m² on day 1)
Number of subjects: 385
Study 25997818 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m² on day 1) alone
Number of subjects: 385
Study 23245197 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM) treatment
Number of subjects: 93
Study 23245197 — intervention group
Group type: COMPARATOR
Intervention: No Contingency Management (non-CM)
Number of subjects: 93
Study 23245197 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment delay discounting
Number of subjects: 93
Study 23245197 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment discounting
Number of subjects: 93
Study 21982465 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day cefazolin prophylaxis
Number of subjects: 231
Study 21982465 — intervention group
Group type: COMPARATOR
Intervention: 3-day cefazolin prophylaxis
Number of subjects: 231
Study 19167238 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO (15,000 IE of rHuEPO)
Number of subjects: 3
Study 19167238 — intervention group
Group type: COMPARATOR
Intervention: LPS alone
Number of subjects: 3
Study 19167238 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO and LPS
Number of subjects: 3
Study 17123158 — intervention group
Group type: EXPERIMENTAL
Intervention: Race-based peremptory challenges
Number of subjects: 0
Study 17123158 — intervention group
Group type: EXPERIMENTAL
Intervention: Justification of peremptory challenges
Number of subjects: 0
Study 15552197 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical NSAIDs for three days preoperatively
Number of subjects: 0
Study 11515642 — intervention group
Group type: EXPERIMENTAL
Intervention: sorbitol/carbamide gum
Number of subjects: 602
Study 11515642 — intervention group
Group type: EXPERIMENTAL
Intervention: sorbitol gum
Number of subjects: 602
Study 11515642 — intervention group
Group type: EXPERIMENTAL
Intervention: xylitol gum
Number of subjects: 602
Study 11515642 — intervention group
Group type: COMPARATOR
Intervention: control gum
Number of subjects: 602
Study 11515642 — intervention group
Group type: EXPERIMENTAL
Intervention: no gum
Number of subjects: 602
Study 9609411 — intervention group
Group type: EXPERIMENTAL
Intervention: ATIII (total dose 24000 units)
Number of subjects: 120
Study 9609411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 9609411 — intervention group
Group type: EXPERIMENTAL
Intervention: ATIII
Number of subjects: 120
Study 7924773 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c of the dense erythrocytes in mothers of heavy-for-dates infants (mean +/- SD; 5.86 +/- 0.68%)
Number of subjects: 59
Study 7924773 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal body mass index (BMI) in mothers of heavy-for-dates infants (mean +/- SD; 26.5 +/- 2.9 kg/m2)
Number of subjects: 59
Study 7924773 — intervention group
Group type: EXPERIMENTAL
Intervention: Occurrence of high levels of HbA1c of the dense erythrocytes
Number of subjects: 59
Study 7924773 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal BMI
Number of subjects: 59
Study 7924773 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycated albumin levels
Number of subjects: 59
Study 7924773 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between high levels of HbA1c of the dense erythrocytes and maternal obesity
Number of subjects: 59
Study 2369792 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose hydration (group 1)
Number of subjects: 20
Study 2369792 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic saline (group 2)
Number of subjects: 20
Study 367043 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.05 mg twice daily
Number of subjects: 49
Study 367043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 367043 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyramine 125 mg
Number of subjects: 49
Study 367043 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for tyramine trial)
Number of subjects: 49
Study 30783069 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based Cognitive-Behavioural Therapy (iCBT), 8-week therapist-guided
Number of subjects: 174
Study 30783069 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control Group (CG)
Number of subjects: 174
Study 27797015 — intervention group
Group type: EXPERIMENTAL
Intervention: Perseverative cognition
Number of subjects: 56
Study 27797015 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem solving
Number of subjects: 56
Study 27797015 — intervention group
Group type: COMPARATOR
Intervention: Mind wandering
Number of subjects: 56
Study 26446153 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive training sessions for nursing staff (two 4-hour sessions) to recognize potentially harmful medications
Number of subjects: 227
Study 26446153 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 227
Study 23495767 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambu aScope
Number of subjects: 60
Study 23495767 — intervention group
Group type: COMPARATOR
Intervention: Olympus BF videobronchoscope
Number of subjects: 60
Study 21826782 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea and phlebotomy for 30 months
Number of subjects: 0
Study 21826782 — intervention group
Group type: COMPARATOR
Intervention: Transfusions and chelation (standard therapy)
Number of subjects: 0
Study 19299471 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir
Number of subjects: 101
Study 19299471 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir plus nevirapine (LPV/r+NVP)
Number of subjects: 101
Study 19299471 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed switching for 24 weeks)
Number of subjects: 101
Study 17229772 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 37.5 mg twice a day for 4 weeks
Number of subjects: 80
Study 17229772 — intervention group
Group type: COMPARATOR
Intervention: Clonidine 0.075 mg twice a day for 4 weeks
Number of subjects: 80
Study 15049169 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia
Number of subjects: 0
Study 11279398 — intervention group
Group type: EXPERIMENTAL
Intervention: Balneotherapy with arsenical-ferruginous water
Number of subjects: 30
Study 11279398 — intervention group
Group type: COMPARATOR
Intervention: Placebo vaginal suppositories
Number of subjects: 30
Study 9623518 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 13
Study 9623518 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 13
Study 7930697 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-PCR assay for MCV RNA on blood samples from case-patients
Number of subjects: 20
Study 7930697 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-PCR assay for MCV RNA on PBMC RNA preparations
Number of subjects: 20
Study 7930697 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleotide sequencing of G2 and S segment amplimers
Number of subjects: 20
Study 7930697 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing of convalescent samples
Number of subjects: 20
Study 2491460 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg o.m.
Number of subjects: 98
Study 2491460 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 800 mg nocte
Number of subjects: 98
Study 31904841 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resource telecare intervention
Number of subjects: 25
Study 31904841 — intervention group
Group type: COMPARATOR
Intervention: Low-resource telecare intervention
Number of subjects: 25
Study 30418116 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Cannabis Therapy (MCT) after 3 months of Standardised Analgesic Therapy (SAT)
Number of subjects: 31
Study 30418116 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Cannabis Therapy (MCT)
Number of subjects: 31
Study 30418116 — intervention group
Group type: COMPARATOR
Intervention: Standardised Analgesic Therapy (SAT)
Number of subjects: 31
Study 28196254 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp cooling (n=119)
Number of subjects: 182
Study 28196254 — intervention group
Group type: COMPARATOR
Intervention: Control (n=63)
Number of subjects: 182
Study 25968836 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal DHEA (6.5 mg daily for 52 weeks)
Number of subjects: 668
Study 25968836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 668
Study 23679290 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle practices including smoking, alcohol consumption, exercise, sun protection, and fruit consumption.
Number of subjects: 1100
Study 21728418 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace Triple P (WPTP)
Number of subjects: 121
Study 21728418 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control (WLC)
Number of subjects: 121
Study 19779467 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1,500 mg per day)
Number of subjects: 31
Study 19779467 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 31
Study 16540815 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine (400‐600 mg/day)
Number of subjects: 50
Study 16540815 — intervention group
Group type: COMPARATOR
Intervention: divalproex (serum level 80‐120 microg/mL)
Number of subjects: 50
Study 14709947 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine CR
Number of subjects: 300
Study 14709947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 11460608 — intervention group
Group type: EXPERIMENTAL
Intervention: Test Dentifrice containing pyrophosphate, tripolyphosphate and a copolymer in a 0.243% sodium fluoride/silica base
Number of subjects: 91
Study 11460608 — intervention group
Group type: COMPARATOR
Intervention: Positive Control Dentifrice containing tetrapotassium pyrophosphate, disodium pyrophosphate and tetrasodium pyrophosphate in a 0.243% sodium fluoride/silica base
Number of subjects: 91
Study 9510662 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP breathing at 10 cmH2O for 25 minutes
Number of subjects: 9
Study 9510662 — intervention group
Group type: EXPERIMENTAL
Intervention: BiPAP breathing at 10/4 cmH2O for 25 minutes
Number of subjects: 9
Study 8238157 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 80
Study 8238157 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulfate
Number of subjects: 80
Study 8238157 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline
Number of subjects: 80
Study 3936908 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral L-carnitine supplementation (70 mumol/l/kg/24 h in 24 mL of 5% dextrose) for seven days
Number of subjects: 12
Study 3936908 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation (dextrose 5%, 24 cc/24 h) for seven days
Number of subjects: 12
Study 3936908 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral L-carnitine supplementation
Number of subjects: 12
Study 31079938 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg plus bevacizumab 15 mg/kg intravenously once every 3 weeks
Number of subjects: 915
Study 31079938 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib 50 mg orally once daily for 4 weeks on, 2 weeks off
Number of subjects: 915
Study 31079938 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus bevacizumab
Number of subjects: 915
Study 31079938 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 915
Study 28704309 — intervention group
Group type: EXPERIMENTAL
Intervention: ECC/ECC
Number of subjects: 40
Study 28704309 — intervention group
Group type: EXPERIMENTAL
Intervention: CON/CON
Number of subjects: 40
Study 28704309 — intervention group
Group type: COMPARATOR
Intervention: Control (no training)
Number of subjects: 40
Study 27089460 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher aerobic fitness levels
Number of subjects: 290
Study 27089460 — intervention group
Group type: EXPERIMENTAL
Intervention: Increases in aerobic fitness
Number of subjects: 290
Study 27089460 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of fitness
Number of subjects: 290
Study 25122645 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25, 0.5, and 1.0 L of milk
Number of subjects: 5
Study 25122645 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk exosomes added to cell culture media
Number of subjects: 5
Study 25122645 — intervention group
Group type: COMPARATOR
Intervention: Milk miRNA-depleted diet for 4 weeks
Number of subjects: 5
Study 25122645 — intervention group
Group type: COMPARATOR
Intervention: Broccoli sprout feeding studies
Number of subjects: 5
Study 22425473 — intervention group
Group type: EXPERIMENTAL
Intervention: EP and ToM video-based training, n=27
Number of subjects: 52
Study 22425473 — intervention group
Group type: COMPARATOR
Intervention: Standard social cognitive rehabilitation treatment, n=24
Number of subjects: 52
Study 22425473 — intervention group
Group type: COMPARATOR
Intervention: Time-matched control group, n=24
Number of subjects: 52
Study 18819958 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot orthoses fitted by a physiotherapist
Number of subjects: 42
Study 18700378 — intervention group
Group type: EXPERIMENTAL
Intervention: Resonance Frequency Analysis (Osstell)
Number of subjects: 65
Study 18700378 — intervention group
Group type: EXPERIMENTAL
Intervention: Damping Capacity Assessment (Periotest)
Number of subjects: 65
Study 16379551 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein hydrolysate prepared with Aspergillus oryzae protease
Number of subjects: 144
Study 16379551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 12456597 — intervention group
Group type: EXPERIMENTAL
Intervention: Human albumin administration
Number of subjects: 378
Study 12456597 — intervention group
Group type: COMPARATOR
Intervention: Placebo or no treatment (Control)
Number of subjects: 378
Study 10468903 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-677 (25 mg/day; n = 12)
Number of subjects: 24
Study 10468903 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 12)
Number of subjects: 24
Study 8612318 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 75 mg/m2
Number of subjects: 18
Study 8612318 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 90 mg/m2
Number of subjects: 18
Study 8612318 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 105 mg/m2
Number of subjects: 18
Study 8612318 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 120 mg/m2
Number of subjects: 18
Study 2007742 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg Beclomethasone dipropionate (BD) enemas for 28 days
Number of subjects: 32
Study 2007742 — intervention group
Group type: COMPARATOR
Intervention: 5 mg Betamethasone phosphate (BP) enemas for 28 days
Number of subjects: 32
Study 6347921 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulconazole nitrate cream 1%
Number of subjects: 96
Study 6347921 — intervention group
Group type: COMPARATOR
Intervention: Miconazole nitrate cream 2% (twice daily application)
Number of subjects: 96
Study 6347921 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulconazole nitrate cream 1% (bid)
Number of subjects: 96
Study 6347921 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 96
Study 31331390 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori sero-positive
Number of subjects: 934
Study 31331390 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrophic gastritis (PGI < 30 μg/L or PGI: PGII < 3.0)
Number of subjects: 934
Study 31331390 — intervention group
Group type: EXPERIMENTAL
Intervention: Past H. pylori infection (sero-negative to H. pylori IgG antibody) with atrophic gastritis
Number of subjects: 934
Study 31331390 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for age, sex, and religiosity
Number of subjects: 934
Study 31331390 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 934
Study 31331390 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 934
Study 28121288 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised and tailored letter from the general practitioner and an invitation to a taster session.
Number of subjects: 4384